Shionogi’s novel antibiotic selected for UK pilot subscription reimbursement model
pharmafile | December 21, 2020 | News story | Sales and Marketing | NICE, Shionogi, antibiotic
Japanese pharmaceutical company Shionogi today announced that NICE and NHS England and Improvement (NHSE&I) have selected its novel antibiotic Fetcroja (cefiderocol) for inclusion in a pilot subscription reimbursement model in the UK, which ‘de-links’ payment from volume of use.
The scheme that selected Shionogi’s antibiotic aims to to pilot a model that reimburses companies for antimicrobials based on a health technology assessment of their value to the NHS, rather than the volumes used. The selection process by NICE and NHSE&I was designed to favour products which meet a key need in the UK while also addressing disease areas of international importance, in particular those drugs which treat serious infections including blood stream infection (BSI), sepsis, and hospital or ventilator acquired pneumonia (HAP/VAP).
A range of factors, such as degree of novelty, activity against the WHO critical priority pathogen list, surety of supply, the supplier’s demonstrated commitment to antimicrobial, and environmental stewardship and commitment to support surveillance were considered. NICE will further assess cefiderocol next year, and implementation of the subscription-based payment is due to commence in April 2022.
Antimicrobial resistance is a major health burden; there are around 25,000 deaths per year in the EU and 5,000 deaths in the UK from an infection with multidrug-resistant bacteria. Infections caused by carbapenem-resistant Gram-negative bacteria are often associated with a high mortality rate.
Dr Mark Hill.Global Head of Market Access at Shionogi, said: “We are delighted that NICE and NHSE&I have recognised the important role of Shionogi and our novel antibiotic, cefiderocol, in the fight against antimicrobial resistance.”
Takuko Sawada, Executive Vice President, Shionogi, added: “This is an important step in making the market for new antibiotics more predictable and sustainable. We hope that it will set a positive precedent for further innovative payment mechanisms in the future.”
Darcy Jimenez
Related Content
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Dual immunotherapy for bowel cancer now available under NHS
Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in …
